Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.

Acumen Pharmaceuticals Reports Cash Balance Of $110.2M As Of June 30, 2026, Expected to Cash Runway Into Early 2027

Acumen Pharmaceuticals Q2 EPS $(0.45) Misses $(0.34) Estimate

8-K filing — Acumen Pharmaceuticals, Inc. (ABOS)

Filed: 2026-08-12 AccNo: 0001628280-26-055940 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits